Suppr超能文献

牛磺酸、溴莫尼定和倍他洛尔对退化的rd10小鼠视网膜振荡调制和刺激效率的影响。

Effects of taurine, brimonidine and betaxolol on oscillation modulation and stimulation efficiency in degenerated rd10 mouse retinas.

作者信息

Schaffrath Kim, Ingensiep Claudia, Müller Frank, Walter Peter, Johnen Sandra

机构信息

Department of Ophthalmology, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.

Institute of Biological Information Processing, Molecular and Cellular Physiology (IBI-1), Forschungszentrum Jülich GmbH, Wilhelm-Johnen-Straße, 52428, Jülich, Germany.

出版信息

Sci Rep. 2025 Jun 20;15(1):20209. doi: 10.1038/s41598-025-06440-9.

Abstract

The rd10 mouse is a widely used model for degenerative retinal diseases such as retinitis pigmentosa (RP). Its retina shows rhythmic spontaneous activity at a frequency of three to seven Hz, and the retinal ganglion cells (RGCs) are less electrically excitable. We hypothesize that the electrical excitability can be improved by suppressing the oscillations using the neuroprotective drugs 2-aminoethanesulphonic acid (taurine), brimonidine and betaxolol. These are involved in calcium homeostasis and may play a crucial role in neuroprotection and excitotoxicity by preventing Ca overload. Spontaneous activity and responses to electrical stimulation of isolated retinas from 3- to 4-month-old rd10 mice were recorded using multielectrode arrays. At defined times, the neuroprotectants were repeatedly added to the medium according to a standardized protocol to analyze the reproducibility and reversibility of their effects. Taurine and betaxolol significantly reduced oscillations and bursting behavior and ameliorated electrical efficiency. Brimonidine only reduced the frequency of oscillations. The effects on oscillation, spontaneous firing frequency, bursting behavior and stimulation efficiency were reproducible and reversible. The drugs tested appear to be promising therapeutic candidates for improving the residual function of RGCs. They will be further investigated and combined with other RP treatments, such as retinal prostheses, in the future.

摘要

rd10小鼠是一种广泛用于视网膜色素变性(RP)等退行性视网膜疾病的模型。其视网膜以3至7赫兹的频率呈现节律性自发活动,并且视网膜神经节细胞(RGCs)的电兴奋性较低。我们假设使用神经保护药物2-氨基乙磺酸(牛磺酸)、溴莫尼定和倍他洛尔抑制振荡可以提高电兴奋性。这些药物参与钙稳态,并且可能通过防止钙超载在神经保护和兴奋性毒性中发挥关键作用。使用多电极阵列记录3至4月龄rd10小鼠分离视网膜的自发活动和对电刺激的反应。在特定时间,根据标准化方案将神经保护剂反复添加到培养基中,以分析其作用的可重复性和可逆性。牛磺酸和倍他洛尔显著降低了振荡和爆发行为,并改善了电效率。溴莫尼定仅降低了振荡频率。对振荡、自发放电频率、爆发行为和刺激效率的影响是可重复和可逆的。所测试的药物似乎是改善RGCs残余功能的有前景的治疗候选药物。未来将对它们进行进一步研究,并与其他RP治疗方法(如视网膜假体)相结合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d95a/12181435/44124f3ed2c7/41598_2025_6440_Fig1_HTML.jpg

相似文献

2
Neuroprotection for treatment of glaucoma in adults.
Cochrane Database Syst Rev. 2017 Jan 25;1(1):CD006539. doi: 10.1002/14651858.CD006539.pub4.
3
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.

本文引用的文献

1
Geographic Atrophy in Age-Related Macular Degeneration.
Dtsch Arztebl Int. 2025 Feb 7;122(3):82-88. doi: 10.3238/arztebl.m2025.0003.
3
Prosthetic Visual Acuity with the PRIMA Subretinal Microchip in Patients with Atrophic Age-Related Macular Degeneration at 4 Years Follow-up.
Ophthalmol Sci. 2024 Mar 7;4(5):100510. doi: 10.1016/j.xops.2024.100510. eCollection 2024 Sep-Oct.
4
Concerning Syfovre Approval for Geographic Atrophy.
JAMA Ophthalmol. 2024 Feb 1;142(2):85-86. doi: 10.1001/jamaophthalmol.2023.5584.
5
Avacincaptad Pegol: First Approval.
Drugs. 2023 Oct;83(15):1447-1453. doi: 10.1007/s40265-023-01948-8.
6
Taurine: a promising nutraceutic in the prevention of retinal degeneration.
Neural Regen Res. 2024 Mar;19(3):606-610. doi: 10.4103/1673-5374.380820.
7
Preclinical Evaluation of a Novel Once-a-Day Brimonidine Ophthalmic Nanosuspension.
J Ocul Pharmacol Ther. 2023 Aug 30. doi: 10.1089/jop.2023.0038.
8
Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Ophthalmol Retina. 2023 Jul;7(7):573-585. doi: 10.1016/j.oret.2023.03.001. Epub 2023 Mar 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验